MedPath

Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal

Not Applicable
Conditions
Rectal Neoplasm
Interventions
Procedure: Hand-sewn coloanal anastomosis
Procedure: Two staged Turnbull-Cutait procedure
Procedure: Ultralow anterior rectal resection with total mesorectal excision
Registration Number
NCT01766661
Lead Sponsor
Hospital Universitari de Bellvitge
Brief Summary

The aim of this study is to decrease the morbidity by 30% using the Turnbull-Cutait procedure in comparison to the standard surgery for low rectal cancer. The investigators compare quality of life, faecal incontinence and recurrence of neoplasm in patients who received standard colo-anal anastomosis with protective ileostomy or two-staged Turnbull-Cutait colo-anal anastomosis after Low Anterior Resection for rectal cancer.

Detailed Description

Anastomotic leak represents the most frequent complication after rectal cancer surgery and a lateral covering ileostomy is usually performed to reduce its incidence. Other important consequences of rectal cancer surgery are alterations in bowel habits and function and a negative impact on quality of life. This prospective, randomized, multicenter and controlled trial compares post-operative complications, quality of life, faecal incontinence and recurrence rate in patients treated for low rectal cancer with colo-anal anastomosis protected by a lateral ileostomy or with a two-staged Turnbull-Cutait colo-anal anastomosis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
92
Inclusion Criteria
  • Patients with adenocarcinoma of the lower-middle third of the rectum proctoscopy established by rigid proctoscopy, with histological confirmation and candidates of colo-anal anastomosis;
  • Patients over 18 years and under 75 years, who can tolerate neoadjuvant and surgical treatment;
  • Patients who undergo an ultra-low anterior rectal resection with total mesorectal excision and nerve and sphincter-sparing with curative intention
  • Any extension of the primary tumor (T 1-2-3-4) according to the TNM classification;
  • Patients with or without lymph node metastasis (N - / +) and with or without resectable distant metastases;
  • Patients clinically without fecal incontinence prior to the current illness and with a Wexner incontinence Score less than or equal to 5;
  • Patients ASA I, II or III and adequate hematological, renal and hepatic function;
  • Patients who signed informed consent.
Exclusion Criteria
  • Altered cognitive state(eg mental retardation or dementia) that prevents collaboration in the study or patients who can neither read nor write
  • Fecal incontinence (Wexner equal to or greater than 6);
  • Previous surgery or proctological, colonic and anorectal functional disease
  • Diagnosis of synchronous colorectal or any other active neoplasm;
  • Patients ASA IV, V;
  • Pregnancy and lactation;
  • Rejection of the patient to sign the consent form.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Two stage Turnbull-Cutait anastomosisUltralow anterior rectal resection with total mesorectal excisionTwo staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
Coloanal anastomosis with ileostomyHand-sewn coloanal anastomosisHand-sewn coloanal anastomosis protected by a loop ileostomy
Coloanal anastomosis with ileostomyUltralow anterior rectal resection with total mesorectal excisionHand-sewn coloanal anastomosis protected by a loop ileostomy
Two stage Turnbull-Cutait anastomosisTwo staged Turnbull-Cutait procedureTwo staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
Primary Outcome Measures
NameTimeMethod
post-operative morbiditywithin the first 30 days after surgery
Secondary Outcome Measures
NameTimeMethod
local and/or distant recurrence of neoplasm3 years
Quality of life3 years

by COREFO questionnaire.

Fecal incontinence3 years

by Wexner Incontinence Score

Trial Locations

Locations (4)

Istituto Nazionale Tumori "Fondazione G, Pascale" - IRCCS

🇮🇹

Naples, Italy

Vall d'Hebron Universitary Hospital

🇪🇸

Barcelona, Spain

Corporació Sanitària Parc Taulí Hospital Universitari

🇪🇸

Sabadell, Barcelona, Spain

Bellvitge University Hospital

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath